- Conditions
- Crohns Disease
- Interventions
- Certolizumab
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 85
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Crohn's Disease
- Interventions
- certolizumab pegol
- Biological
- Lead sponsor
- Atlanta Gastroenterology Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab Pegol
- Drug
- Lead sponsor
- Shafran Gastroenterology Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Winter Park, Florida
- Conditions
- Crohns Disease, Fistula, Abscess
- Interventions
- Exam under anesthesia (EUA)
- Procedure
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Pittsburgh, Pennsylvania • Nashville, Tennessee
- Conditions
- Healthy
- Interventions
- Prefilled syringe (PFS), e-Device
- Device
- Lead sponsor
- UCB BIOSCIENCES, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Walnut Creek, California • Wheaton, Maryland + 3 more
- Conditions
- Psoriasis
- Interventions
- Secukinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 17,743 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab pegol (CDP870)
- Drug
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 26
- States / cities
- Huntsville, Alabama • Paradise Valley, Arizona • La Jolla, California + 23 more
- Conditions
- Psoriasis, Atopic Dermatitis
- Interventions
- In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
- Device · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab Pegol
- Drug
- Lead sponsor
- UCB Celltech
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 21 more
- Conditions
- Psoriasis, Plaque Psoriasis
- Interventions
- Certolizumab Pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- SHINGRIX
- Biological
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab pegol, Placebo
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 539 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 31
- States / cities
- San Francisco, California • Gainesville, Florida • Atlanta, Georgia + 28 more
- Conditions
- Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
- Interventions
- e-Device
- Drug
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 22
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 15 more
- Conditions
- Lung Cancer, Lung Cancer Stage II, Lung Cancer Stage III
- Interventions
- Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Certolizumab, Nivolumab, Paclitaxel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Crohn's Disease, IBD
- Interventions
- Anti-TNF, Steroids
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Hershey, Pennsylvania • Nashville, Tennessee
- Conditions
- Rheumatoid Arthritis, Cardiovascular Disease
- Interventions
- Certolizumab
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 35 Years to 90 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Ulcerative Colitis and Crohn's Disease
- Interventions
- Vedolizumab, Other Biologic Agents
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 54 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab Pegol (CDP870)
- Biological
- Lead sponsor
- UCB Pharma SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 596 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 40 more
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
- Biological
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Spondyloarthropathies
- Interventions
- CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
- Biological · Other
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, Certolizumab pegol
- Other · Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
- Conditions
- Crohn's Disease
- Interventions
- certolizumab pegol 400 mg, Placebo
- Biological · Other
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 51 more